Search Results
237 items found for "Addex Therapeutics"
- Reversible Photocontrol of Dopaminergic Transmission in Wild-Type Animals
animals and opens the way to remotely controlling dopaminergic neurotransmission for fundamental and therapeutic
- 📰 GPCR Buzz: August 5-11, 2024 | Top Highlights from DrGPCR University!
From omics to epigenetics The impact of nanobodies on GPCR structural biology and their potential as therapeutic complexes with MolBoolean Screening GPR75 Modulators Using Medium-Throughput Reporter Gene Assay GPCR Therapeutics
- Exploring pharmacological inhibition of G q/11 as an analgesic strategy
These can be used either as stand-alone therapeutics or to improve the safety profile of opioid drugs
- Structures of oxysterol sensor EBI2/GPR183, a key regulator of the immune response
new insight into how EBI2 is activated by an oxysterol ligand and will facilitate the development of therapeutic
- Activation of the human chemokine receptor CX3CR1 regulated by cholesterol
receptor subfamily, CX3CR1 binds to its sole endogenous ligand CX3CL1, which shows notable potential as a therapeutic
- Isoform-and ligand-specific modulation of adhesion GPCR ADGRL3/Latrophilin3 by a synthetic binder
using unique tools, and thus establishes a foundation for the development of fine-tuned aGPCR-targeted therapeutics
- Crinetics Pharmaceuticals Announces Pricing Of Underwritten Common Stock Offering
clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics
- 📰 GPCR Weekly News, May 22 to 28, 2023
Therapeutic antagonism of the neurokinin 1 receptor in endosomes provides sustained pain relief. Patients with Idiopathic Pulmonary Fibrosis Exscientia Business Update for First Quarter 2023 Structure Therapeutics
- Chronic itch: emerging treatments following new research concepts
itch processing, the numerous mediators and receptors involved has led to a large variety of possible therapeutic
- Orion Announces The Rapid Lead Optimization Of Ob-004 - A Ccr2 Antagonist
Ottawa, Ontario, Canada, Nov. 30, 2021 -- Orion Biotechnology , a clinical stage company unlocking the therapeutic
- A central alarm system that gates multi-sensory innate threat cues to the amygdala
The identification of unified innate threat pathways may provide insights into developing therapeutic
- Extracellular signal-regulated kinases – a potential pathway for GPCR-targeted drug discovery
In summary, targeting GPCR-activated ERK pathways represents a promising strategy for developing new therapeutics ERK-dependent apoptosis as a potential therapeutic strategy for cancer. Cells, 10(10), 2509.
- Nanobodies as Probes and Modulators of Cardiovascular G Protein-Coupled Receptors
nanobodies with tailored specificities may expand the impact of these tools for both basic science and therapeutic
- Orion Shares New Data on its Latest Best-in-Class Drug Candidate
10, 2022 — Orion Biotechnology Canada Ltd, a drug discovery and development company unlocking the therapeutic
- Tracking receptor motions at the plasma membrane reveals distinct effects of ligands on CCR5...
However, how these states impact GPCRs biological function and therapeutic targeting remains incompletely
- From DNA day to GPCR genomics
GPCR-targeted drugs, and the exploration of GPCRs as key regulators of physiological processes and therapeutic analysis, have facilitated drug discovery and design targeting GPCRs, leading to the development of novel therapeutics
- Immunomodulatory Role of Neuropeptides in the Cornea
maintaining the homeostasis of the ocular surface, alterations in disease settings, and the possible therapeutic
- 📰 GPCR Weekly News, June 5 to 11, 2023
Novartis bolsters innovative medicines strategy and renal pipeline with agreement to acquire Chinook Therapeutics Confo Therapeutics Enters Into Research Collaboration For GPCR-Targeting Antibody Discovery With AbCellera
- Deciphering the signaling mechanisms of β-arrestin1 and β-arrestin2 in regulation of cancer cell...
Understanding these processes has important implications for understanding the therapeutic intervention
- 📰 GPCR Weekly News, March 11 to 17, 2024
Insights into GPCR Function Time-resolved cryo-EM of G-protein activation by a GPCR Industry News Domain Therapeutics Protein Structures Newly discovered adhesion GPCR mayo controls midgut development in Drosophila Karuna Therapeutics
- 📰 GPCR Weekly News, February 26 to March 3, 2024
and drug discovery in endocrinology and metabolism Reviews, GPCRs, and more Butyrate as a promising therapeutic cadherin G protein-coupled receptors that bind cry toxins of Bacillus thuringiensis Industry News Domain Therapeutics
- Lipid Modulation of a Class B GPCR: Elucidating the Modulatory Role of PI(4,5)P 2 Lipids
interacting with the Glucagon receptor (GCGR), which constitutes an important target for diabetes and obesity therapeutics
- GPCR Signaling and mTORC1 Regulation
of mTOR complex 1 (mTORC1) is typically observed in human disease and continues to be an important therapeutic
- TRPM3 in the eye and in the nervous system - from new findings to novel mechanisms
clear picture is needed to unravel TRPM3's full potential as experimental tool, diagnostic marker and therapeutic
- Deciphering the signaling mechanisms of β-arrestin1 and β-arrestin2 in regulation of cancer cell...
Understanding these processes has important implications for understanding the therapeutic intervention
- Harnessing Deep Mutational Scanning for Enhanced Drug Discovery
development of more personalised therapies tailored to the genetic makeup of individual patients, enhancing therapeutic that can drive the early stages of target and lead identification, combat drug resistance, and refine therapeutic
- Rhodopsin as a Molecular Target to Mitigate Retinitis Pigmentosa
Currently, there is no cure for RP, and the therapeutic options are limited.
- Structural basis for receptor selectivity and inverse agonism in S1P5 receptors
Several S1PR therapeutic drugs have been developed to treat these diseases; however, they lack receptor